
1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
Powderly, J., Patel, M.R., Lee, J.J., Brody, J., Meric-Bernstam, F., Hamilton, E., Ponce Aix, S., Garcia-Corbacho, J., Bang, Y-J., Ahn, M-J., Rha, S.Y., Kim, K-P., Gil Martin, M., Wang, H., Lazorchak,Volume:
28
Langue:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx376.007
Date:
September, 2017
Fichier:
PDF, 65 KB
english, 2017